The company leverages over 10 years of mRNA research and development expertise to develop therapeutic candidates and vaccines in collaboration with Sanofi's vaccine and drug development capabilities. Its platform targets multiple therapeutic areas including infectious diseases, rare genetic disorders, and oncology, positioning it as a core pillar of Sanofi's mRNA innovation strategy.
Cyborg Score Rationale
As a Sanofi subsidiary with validated mRNA platform technology and multiple clinical programs, Translate Bio has strong technical credentials and access to Sanofi's resources. However, post-acquisition integration and lack of independent operational transparency limit independent assessment. The company's long history of R&D success and strategic positioning within a major pharmaceutical company provide stability.
Top Insights
Acquired by Sanofi (September 2021) for $3.2B, now a key asset in Sanofi's mRNA Center of Excellence
Lead program MRT5005 in Phase I/II clinical trial for cystic fibrosis treatment
Over 10 years of mRNA research and development foundation supporting multiple therapeutic areas
Strategic collaboration with Sanofi Pasteur advancing mRNA vaccines for COVID-19, influenza, and other infectious diseases
Named Competitors
Moderna — mRNA-based vaccines and therapeutics
BioNTech — Immunotherapy and vaccine development using mRNA
Sanofi — Parent company; global pharmaceutical and vaccine manufacturer
Recent Developments
(February 2021) Announced TBIO 2025 strategic plan emphasizing multiple areas for mRNA value creation
(June 2020) Expanded collaboration with Sanofi Pasteur; received $425 million in upfront payments
(September 2021) Acquisition by Sanofi completed at $38 per share
Open the full interactive Translate Bio, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.